Diffuse lymphomas of B-cell origin represent a heterogeneous group of lymphoid neoplasms. The histologically aggressive subtypes of diffuse B-cell lymphomas include biologically different entities, ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with ...

Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue. There’s a need for access to treatment and a need for better drugs in diffuse large B-cell lymphoma ...

Researchers identified genomic alterations that defined four subtypes of diffuse large B-cell lymphoma that may predict which patients will respond to treatment and have longer OS, according to study ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), ...

Non-Hodgkin's lymphoma is a group of cancers that start in lymphocytes -- your immune system’s infection-fighting white blood cells. Doctors divide it into types based on the kind of lymphocyte each ...